The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
GlobalData on MSN3d
Intra-Cellular bolsters Caplyta data with another Phase III winThe FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal ...
A review of published psychiatric drug trials shows that successful outcomes are more often published, and unsuccessful ...
News Medical on MSN12d
Ozempic effective for patients with chronic kidney damageIn a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic ...
CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity, today announced topline int ...
Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...
Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.
Source Reference: Janik A, et al "Efficacy and safety of esketamine nasal spray as monotherapy in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback